Myrtelle Inc. has commenced commercial-stage manufacturing for its investigational gene therapy product, MYR-101, developed for the treatment of Canavan disease. The initiative marks a key milestone in the company’s journey toward market readiness and expanded patient access. The manufacturing programme
NJ Bio and Charles River Laboratories have entered a strategic alliance to enhance and streamline the development and manufacturing of antibody drug conjugates (ADCs) for their clients. The partnership will integrate both companies’ complementary capabilities, covering early development, optimisation, and
Charles River and Wheeler Bio have announced the completion of an agreement that promises to accelerate the journey from discovery and CMC development to manufacturing. This collaboration aims to streamline the process, reducing the time and resources required to transition from the discovery
Stay ahead of trends and best practices
Exclusive downloads and podcasts
Get invites to special events and meetups 
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
